中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2014年
3期
88-90
,共3页
前列腺素E1%肝硬化%临床疗效%安全性
前列腺素E1%肝硬化%臨床療效%安全性
전렬선소E1%간경화%림상료효%안전성
liver cirrhosis%prostaglandin E1%clinical effect%security
目的：观察前列腺素E1治疗肝硬化的临床疗效，并对其安全性进行评估。方法选取2011年7月～2012年7月台州医院收治的肝硬化患者68例，随机均分为治疗组（n＝34）和对照组（n＝34）。对照组接受常规药物治疗，治疗组在对照组基础上接受前列腺素E1治疗，对比分析2组疗效及不良反应。结果与治疗前相比，治疗后2组患者白蛋白数量均明显增加，治疗组由（27.9±4.1）g/L增加到（36.5±4.3）g/L，对照组由（27.8±4.0）g/L增加到（31.7±4.2）g/L，差异均有统计学意义（P＜0.05）；2组间比较，差异也有统计学意义（P＜0.05）。治疗后，2组患者丙氨酸氨基转移酶和门冬氨酸氨基转移酶含量均明显下降（P＜0.05），与对照组相比，治疗组减少更明显（P＜0.05）。治疗组总有效者28例，约占82.35％，对照组仅有11例，约占32.35％，2组比较差异有统计学意义（P＜0.05）。结论前列腺素E 1治疗肝硬化能有效改善患者肝功能指标，临床效果好、安全性高。
目的：觀察前列腺素E1治療肝硬化的臨床療效，併對其安全性進行評估。方法選取2011年7月～2012年7月檯州醫院收治的肝硬化患者68例，隨機均分為治療組（n＝34）和對照組（n＝34）。對照組接受常規藥物治療，治療組在對照組基礎上接受前列腺素E1治療，對比分析2組療效及不良反應。結果與治療前相比，治療後2組患者白蛋白數量均明顯增加，治療組由（27.9±4.1）g/L增加到（36.5±4.3）g/L，對照組由（27.8±4.0）g/L增加到（31.7±4.2）g/L，差異均有統計學意義（P＜0.05）；2組間比較，差異也有統計學意義（P＜0.05）。治療後，2組患者丙氨痠氨基轉移酶和門鼕氨痠氨基轉移酶含量均明顯下降（P＜0.05），與對照組相比，治療組減少更明顯（P＜0.05）。治療組總有效者28例，約佔82.35％，對照組僅有11例，約佔32.35％，2組比較差異有統計學意義（P＜0.05）。結論前列腺素E 1治療肝硬化能有效改善患者肝功能指標，臨床效果好、安全性高。
목적：관찰전렬선소E1치료간경화적림상료효，병대기안전성진행평고。방법선취2011년7월～2012년7월태주의원수치적간경화환자68례，수궤균분위치료조（n＝34）화대조조（n＝34）。대조조접수상규약물치료，치료조재대조조기출상접수전렬선소E1치료，대비분석2조료효급불량반응。결과여치료전상비，치료후2조환자백단백수량균명현증가，치료조유（27.9±4.1）g/L증가도（36.5±4.3）g/L，대조조유（27.8±4.0）g/L증가도（31.7±4.2）g/L，차이균유통계학의의（P＜0.05）；2조간비교，차이야유통계학의의（P＜0.05）。치료후，2조환자병안산안기전이매화문동안산안기전이매함량균명현하강（P＜0.05），여대조조상비，치료조감소경명현（P＜0.05）。치료조총유효자28례，약점82.35％，대조조부유11례，약점32.35％，2조비교차이유통계학의의（P＜0.05）。결론전렬선소E 1치료간경화능유효개선환자간공능지표，림상효과호、안전성고。
Objective To observe the clinical effects of prostaglandin E1 on liver cirrhosis patients and evaluate its security. Methods 68 cases with liver cirrhosis admitted in Luqiao hospital were randomly divided into experimental group(34 cases)and control group(34 cases)equally. Patients in control group were received normal therapy,while in experimental group were added prostaglandin E1 on basis of normal therapy. The efficacy and adverse reactions were observed and compared. Results Compared with before treatment,the average value of albumin in two groups were increased obviously,which in experimental group from (27.9 ±4.1)g/L to (36.5 ±4.3)g/L,control group from (27.8 ±4.0)g/L to (31.7 ±4.2)g/L,the differences were significant(P<0.05 ),and the difference between two groups was significant(P<0.05 ),too. The content of alanine aminotransferase and aspartase aminotransferase in two groups were decreased significantly(P<0.05 ),and experimental group was more lower than control group(P<0.05 ). The number of effcacy in experimental group was 28 and account for 82.35%,while in control group was 1 1 and account for 32.35%,the difference was significant(P<0.05). Conclusion Prostaglandin E1 can improve liver function,and has good clinical effects and high security in treatment with liver cirrhosis patients.
